Hematopoietic and Lymphoid Cell Neoplasm Clinical Trial
Official title:
The Adoption of Audio Recording in the Outpatient Supportive Care Center
| Verified date | February 2024 |
| Source | M.D. Anderson Cancer Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study evaluates how patients feel about having an audio recording of their visit to help remember information given to them and share that information with family members and/or caregivers not present during a clinic visit. Information from this study may help evaluate the effectiveness of using technology to help improve patient care by recording consultation recommendations.
| Status | Not yet recruiting |
| Enrollment | 200 |
| Est. completion date | January 30, 2027 |
| Est. primary completion date | January 30, 2027 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patients with the diagnosis of advanced cancer as defined as locally advanced, recurrent or metastatic cancer. Both solid and liquid tumors are eligible for the study - Patients who are seen in the outpatient supportive care center at M.D. Anderson Cancer Center - Patients who have access to a recording device or cellphone with recording technology - Patients who can be contacted 7 to 11 days from the clinic visit that the recording took place - Patients who can sign informed consent - Patients who are able to read and write in English - Patients 18 years or older Exclusion Criteria: - Patients who have been diagnosed with delirium or cognitive impairment. This will be defined by chart review along with review of the MD Anderson Symptom Inventory (MDAS) the day of clinic visit. An MDAS of 7 or greater will be considered to define delirium in this study - Patients who are unwilling to sign informed consent - Patients who have used audio recordings before in clinic visits - Patients who have severe hearing impairments without access to assisted devices or programs to aid in listening to the recorded material |
| Country | Name | City | State |
|---|---|---|---|
| United States | M D Anderson Cancer Center | Houston | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| M.D. Anderson Cancer Center |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Proportion of patients who will select "Complete Agree/Partially Agree" in Question 1 "I found the audio recording useful after the visit" | Will be summarized using proportion along with a 95% confidence interval. | through study completion, an average of 1 year | |
| Primary | Proportion of patients who will select "Complete Agree/Partially Agree" in Question 2 "I was able to effectively discuss my medical condition with my family member(s) and/or caregiver(s) who were not present at the clinical visit | Will be summarized using proportion along with a 95% confidence interval. | through study completion, an average of 1 year | |
| Secondary | Number of times the recording is listened to | Descriptive statistics will be used to summarize the results. Wilcoxon rank sum test or Kruskal-Wallis test will be applied to examine differences in continuous variables between or among patient's demographic/clinical characteristics. | through study completion, an average of 1 year | |
| Secondary | To assess the ease of use of the technology. | Descriptive statistics will be used to summarize the results. Chi squared test or Fisher's exact test will be applied to examine the association between the ease of use of the technology and patient's demographic/clinical characteristics. | through study completion, an average of 1 year | |
| Secondary | To assess the ability to share the information with the patient's family member(s) and/or caregiver(s) if he or she chooses to do so. | Descriptive statistics will be used to summarize the results. Chi-squared test or Fisher's exact test will be applied to examine the association between the ability to share and patient's demographic/clinical characteristics. | through study completion, an average of 1 year | |
| Secondary | To assess the patient perception of whether the audio recording caused any disruption to the clinic | Descriptive statistics will be used to summarize the results. Chi-squared test or Fisher's exact test will be applied to examine the association between the patient perception of whether audio recording caused any disruption to the clinic and patient's demographic/clinical characteristics. | through study completion, an average of 1 year | |
| Secondary | Patient participation rate | The participation rate of patients in this study will be estimate using proportion along with 95% confidence interval. | through study completion, an average of 1 year | |
| Secondary | To explore the association between the frequency of caregivers' use of audio recording | Pearson or Spearman correlation coefficient will be used to assess the association between caregivers' age and frequency of their use of the audio recording. Wilcoxon rank sum test will be applied to examine differences in frequency of caregivers' use of audio recording between their sexes. | through study completion, an average of 1 year | |
| Secondary | To explore the association of the ease of use of the technology and the type of device and application used | Chi-squared test or Fisher's exact test will be applied to examine the association between the ease of use of the technology and the types of recording devices/applications. | through study completion, an average of 1 year |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT05106374 -
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT05660421 -
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
|
Phase 2 | |
| Suspended |
NCT04060849 -
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
|
Phase 1 | |
| Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
| Withdrawn |
NCT04127721 -
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT03712878 -
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
|
Phase 2 | |
| Active, not recruiting |
NCT06062901 -
An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors
|
N/A | |
| Terminated |
NCT04081298 -
eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
|
N/A | |
| Completed |
NCT04983901 -
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
|
Phase 2 | |
| Recruiting |
NCT04188912 -
Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
|
||
| Active, not recruiting |
NCT04592250 -
Financial Toxicity in Cancer Patients
|
||
| Recruiting |
NCT05112614 -
Role of Gut Microbiome in Cancer Therapy
|
||
| Active, not recruiting |
NCT04296305 -
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
|
Phase 4 | |
| Withdrawn |
NCT04190433 -
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
|
Phase 2 | |
| Terminated |
NCT04083170 -
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
|
Phase 2 | |
| Recruiting |
NCT02464696 -
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
|
N/A | |
| Withdrawn |
NCT04820894 -
Perception of Cure Among Patients With Metastatic Cancer
|
||
| Completed |
NCT03125070 -
Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant
|
Phase 3 | |
| Completed |
NCT01664910 -
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
|
Phase 1/Phase 2 |